ROR gamma (t)
The nuclear receptor retinoic acid receptor-related orphan receptor gamma, also known as ROR gamma (t), is a master regulator of the differentiation of T cells to a pro-inflammatory subtype of T helper cells called Th17. ROR gamma (t) drives the production of key pro-inflammatory cytokines, including interleukin (IL)-17A and IL-17F, and the receptor for IL-23. Antibody therapies targeting these proteins have validated the critical role of the IL-17 pathway in chronic autoimmune-related inflammation. Recent findings have demonstrated that the biological function of ROR gamma (t) can be modulated with small molecules and have advanced this target to the cutting edge of drug discovery.
In February 2015 Lead Pharma and Sanofi started a research collaboration and license agreement to discover, develop and commercialize small molecule therapies directed against ROR gamma (t).
This project is currently in pre-clinical development.